Peregrine Pharma (PPHM) Misses Q1 EPS by 1c

September 8, 2016 4:14 PM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $5.61 million versus the consensus estimate of $13.09 million.


Peregrine Pharma sees Q2 2017 revenue of $20 million, versus the consensus of $12.5 million.

  • Company Reaffirms Revenue Projection of $50 - $55 Million for Full FY 2017 with Growing Backlog of Business

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment